New search | Conferencedetail
Print view

Oncolytic Virotherapy Summit 2017

evvnt Platform / evvnt
Conference themes
The Oncolytic Virotherapy Summit will gather the leaders in immuno-oncolytic virus development to discuss the most up-to-date clinical advances alongside novel innovations being made through the genetic modification of viruses.

Map out the route to market focusing on the strategic advancements needed to improve viral manufacturing yield and scale along with the operational and logistical aspects of delivering oncolytic virotherapies to patients in need.
Professional congress organizer (PCO)
Hanson Wade

Speakers: Matt Mulvey (Benevir Biopharm), Charles Morris (PsiOxus Therapeutics), Stephen Thorne (Western Oncolytics), Frank Tufaro (DNAtrix), Stephen Russell (Vyriad), Angelica Loskog (Lokon Pharma)

Enquiries and Registration:
Mr. Customer Services
Congress fees
USD 3.797,00
(Conference Earlybird (Book by 29/09/17): USD 1999, Conference + 1 Workshop Earlybird (Book by 29/09/17): USD 2498, Conference + 2 Workshop Earlybird (Book by 29/09/17): USD 2997, Workshop only: USD 599, Conference (Standard rate): USD 2799)
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International promotes access to education and training for all regardless of social, geographic and national borders."

Anästhesie in Entwicklungsländern e. V.AGEM - Arbeitsgemeinschaft Ethnomedizin e. V.OÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation European Health Forum GasteinÖsterreichische Akademie der ÄrzteEuropean Public Health Association (EUPHA)Hilfswerk AustriaÖsterreichische Gesellschaft für Public Health


Give us your professional opinion

Start survey

Start survey